# Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

> **NCT01720602** · NA · COMPLETED · sponsor: **University of Washington** · enrollment: 15 (actual)

## Conditions studied

- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** vorinostat
- **DRUG:** anastrozole
- **DRUG:** letrozole
- **DRUG:** exemestane
- **PROCEDURE:** positron emission tomography
- **RADIATION:** F-18 16 alpha-fluoroestradiol
- **RADIATION:** fludeoxyglucose F 18
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01720602
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-03
- **Final completion:** 2020-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01720602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01720602, "Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01720602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*